Form 8-K

8-K — Paysign, Inc.

Accession: 0001683168-26-003722

Filed: 2026-05-12

Period: 2026-05-12

CIK: 0001496443

SIC: 7389 (SERVICES-BUSINESS SERVICES, NEC)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — paysign_8k.htm (Primary)

EX-99.1 — EARNINGS RELEASE (paysign_ex9901.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: paysign_8k.htm · Sequence: 1

Paysign, Inc. 8-K

false

0001496443

2026-05-12

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

May 12, 2026

PAYSIGN,

INC.

(Exact name of registrant as specified in its charter)

Nevada

001-38623

95-4550154

(State or other jurisdiction of incorporation)

(Commission file number)

(I.R.S. Employer Identification Number)

2615 St. Rose Parkway

Henderson, Nevada 89052

(Address of principal executive offices) (Zip Code)

(702) 453-2221

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material

pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

PAYS

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On May 12, 2026, we issued a press

release regarding our financial results for the three months ended March 31, 2026. A copy of the press release is furnished herewith as

Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

As provided in General Instruction

B-2 of SEC Form 8-K, the information set forth in this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed”

for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to

the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as

amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, except as expressly set

forth by specific reference in such filing to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit No.

Description

99.1

Press Release entitled “Paysign’s Patient Affordability

Drives 51% Revenue Growth and Significant Margin Expansion for First Quarter 2026”

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PAYSIGN, INC.

Date: May 12, 2026

By: /s/ Mark Newcomer

Mark Newcomer, President and

Chief Executive Officer

EX-99.1 — EARNINGS RELEASE

EX-99.1

Filename: paysign_ex9901.htm · Sequence: 2

Exhibit 99.1

Earnings Release

Paysign’s Patient Affordability Drives 51% Revenue Growth and

Significant Margin Expansion for First Quarter 2026

Mix Shift Continues to Deliver Expansion in Gross and Operating Margin

Strong Balance Sheet Enables Continued Investment for Profitable Growth

HENDERSON, Nev. – May 12, 2026 – (Business Wire) –

Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability offerings, donor compensation solutions, engagement and

management platforms and integrated payment processing for the life sciences industries, today announced financial results for the first

quarter 2026.

First Quarter 2026 Financial Highlights

First quarter 2026 revenues of $28.04 million, up 50.8% from first quarter 2025

First quarter 2026 pharma revenue increased to $15.68 million, an increase of 81.9% versus first quarter 2025; added 45 net patient affordability programs during the past twelve months, exiting the quarter with 135 active programs

First quarter 2026 plasma revenue increased to $11.75 million, an increase of 24.9% versus first quarter 2025; total net plasma center count increased by 89 during the past 12 months, exiting the quarter with 573 centers

First quarter 2026 operating margin was 23.8% compared to 13.4% in the first quarter 2025

First quarter 2026 net income of $5.44 million, or $0.09 per diluted share, versus net income of $2.59 million, or $0.05 per diluted share in the first quarter 2025

First quarter 2026 adjusted EBITDA of $10.59 million, up 113.4% from $4.96 million for first quarter 2025; diluted Adjusted EBITDA per share of $0.17 versus $0.09 for first quarter 20251

Exited the quarter with $20.55 million of unrestricted cash and zero bank debt

First quarter 2026 restricted cash balances increased 10.4% to $158.95 million from first quarter 2025

First quarter 2026 gross dollar load volume was up 26.4% versus first quarter 2025

First quarter 2026 gross spend volume was up 26.7% versus first quarter 2025

1Adjusted EBITDA and Adjusted EBITDA per share are

non-GAAP metrics used by management to gauge the operating performance of the business – see reconciliation of net income to Adjusted

EBITDA at the end of the press release.

“Paysign delivered a strong start to 2026, with exceptional

top- and bottom-line results that are consistent with our strategic direction and the scalability of the platform we’ve

built,” said Mark Newcomer, President and CEO of Paysign. “Our plasma donor compensation business continues to perform

exceptionally well, and the reception to our SaaS solutions from collectors and plasmapheresis manufacturers across the U.S., Europe

and Asia reinforces our conviction that purpose-built technology, backed by deep industry expertise, creates a competitive

advantage. Patient affordability emerged as our largest revenue contributor in the quarter, with 135 active programs and a strong

pipeline that reflects the trust pharmaceutical manufacturers place in Paysign to help patients access and afford the therapies they

need. As this business grows, we are positioned to deliver long-term value for our shareholders, our customers and the patients we

serve.”

2026 First Quarter Results

Total revenues increased 50.8%, or $9.44 million, to $28.04 million,

up from $18.6 million in the first quarter of 2025. Pharma industry revenue increased 81.9% to $15.68 million from $8.62 million due to

the financial benefit of 45 net pharma patient affordability programs launched during the past 12 months, and a corresponding increase

in monthly management fees, setup fees, claim processing fees and other billable services such as dynamic business rules and customer

service contact center support. Processed claims increased by approximately 49% compared to the first quarter of 2025. Plasma revenue

increased 24.9% to $11.75 million, up from $9.41 million, primarily due to the addition of 89 net plasma centers added during the past

12 months. The average monthly revenue per center increased to $6,671 versus $6,517 and the average number of loads per center increased

for the first time since the industry experienced an inventory correction that began in 2024. We exited the quarter with 573 centers versus

595 centers at the end of 2025 as 20 centers were sold to companies who use a competing provider and two underperforming centers were

closed. Combined, these centers averaged less than $3,500 per month in revenue, performing below the corporate average.

Cost of revenues increased 42.2% due to increased call center support

expense associated with the revenue growth, a new customer service contact center that went live in November 2025 and higher employee

costs. Gross profit improved to 65.0% compared to 62.9% in the first quarter of 2025 as we experienced a greater mix of pharma revenue.

Total operating expenses were $11.55 million compared to $9.20 million

in the first quarter of 2025, an increase of 25.5%. Selling, general and administrative expenses increased by 20.5% to $8.91 million.

Of that amount, stock compensation expense increased 91.0% to $1.28 million. Depreciation and amortization increased by $835 thousand,

or 46.4%, due mainly to the amortization of intangible assets from our Gamma acquisition and continued capitalization of new software

development costs and equipment purchases related to the enhancement to our processing platform. Operating margin was 23.8% compared to

13.4% in the first quarter of 2025.

The company recorded an income tax provision of $2.03 million, resulting

in an effective tax rate of 27.2%, up $1.36 million from the first quarter of 2025 and a tax rate of 20.5%. The effective tax rates reflect

adjustments for discrete quarterly items and tax benefits from stock-based compensation. The significant driver in the discrete item adjustment

in the first quarter of 2026 was primarily related to the increase in stock price at March 31, 2026, when compared to the same period

in the prior year.

Net income for the quarter totaled $5.44 million, or $0.09 per fully

diluted share, an increase of 110.3% from $2.59 million, or $0.05 per fully diluted share, reported in the first quarter of 2025. On a

non-GAAP basis, EBITDA, defined as earnings before interest, taxes, depreciation and amortization, increased by $5.01 million, or 116.9%,

to $9.30 million. Adjusted EBITDA, which excludes stock-based compensation from EBITDA and is used by management to evaluate core operating

performance, rose $5.63 million, or 113.4%, to $10.59 million, or $0.17 per fully diluted share.

Balance Sheet at March 31, 2026

The company’s cash flows increased $14.51 million from December

31, 2025, largely related to the improvement in our operating results, growth of existing customer programs and the launch of new customer

programs.

During the first quarter of 2026, unrestricted cash decreased by $523

thousand to $20.55 million. The decline was attributable to the timing of operating asset and liability payments, capital investments

in intangible and fixed assets and payments of other liabilities associated with the Gamma acquisition. Offsetting these cash outflows

were net income and non-cash adjustments.

Restricted cash increased $15.03 million to $158.95 million from December

31, 2025, primarily related to customer program deposits for our plasma and pharma customers of $9.71 million and an increase in funds

on card of $5.32 million. Restricted cash are funds used for customer card funding and pharmaceutical claim reimbursements with a corresponding

offset under current liabilities.

2026 Outlook

“Our first quarter results exceeded guidance across every line

of the income statement,” commented Jeff Baker, Chief Financial Officer of Paysign. “Revenue, operating margin and net income

all finished above the high end of our prior ranges, driven by fixed cost leverage and a continued mix shift toward patient affordability.

We are reiterating our full-year 2026 ranges, and the momentum from the first quarter supports our confidence in achieving the upper

half of our guidance ranges.”

“The table below details our second quarter and full-year 2026

outlook,” continued Baker. “The second quarter reflects the seasonal pattern we have laid out previously: pharma revenue is

highest in the first quarter as patient affordability claims peak, and plasma builds through the balance of the year. For the full year,

we continue to expect plasma and pharma to contribute roughly equally to revenue, with margins expanding across the income statement and

net income nearly doubling over 2025 as patient affordability scales. With a strong unrestricted cash position, no bank debt and a growing

cash flow profile, we are well positioned to fund our 2026 investment plans and execute against the financial framework we have communicated.”

Second Quarter 2026

Full Year 2026

Revenue

$26.2M – $26.7M

$106.5M – $110.5M

Revenue growth (YoY)

37.5% – 40.0%

30% – 35%

Gross margin

60.0% – 62.0%

60% – 62%

Net income

$3.5M – $4.0M

$13.0M – $16.0M

Diluted EPS

$0.06 – $0.07

$0.21 – $0.26

Adjusted EBITDA2

$7.7M – $8.5M

$30.0M – $33.0M

Adj. EBITDA per diluted share2

$0.13 – $0.14

$0.49 – $0.53

Paysign expects to exit the second quarter of 2026 with 147–150

active patient affordability programs and 555–560 plasma centers.

2 The company is unable to provide a reconciliation

of forward-looking adjusted EBITDA, adjusted EBITDA per diluted share and adjusted EBITDA margin to the most directly comparable GAAP

measure, net income (and net income per diluted share), without unreasonable effort due to the variability, complexity and low visibility

of certain reconciling items. These items include, but are not limited to, stock-based compensation and other non-recurring items, which

could have a material impact on GAAP results.

First Quarter 2026 Financial Results Conference Call Details

The company will hold a conference call at 5:00 p.m. Eastern time on

Tuesday, May 12, 2026, to discuss its first quarter 2026 financial results. The conference call may include forward-looking statements.

The dial-in information for this call is 877.407.2988 (within the U.S.) and +1.201.389.0923 (outside the U.S.). A call replay will be

available until August 12, 2026, and can be accessed by dialing 877.660.6853 (within the U.S.) and +1.201.612.7415 (outside the U.S.),

using passcode 13760115.

Forward-Looking Statements

Certain statements in this press release may be considered forward-looking

under federal securities laws, and we intend that such forward-looking statements be subject to the safe harbor created thereby. All statements,

besides statements of fact included in this release are forward-looking. Such forward-looking statements include, among others, our belief

that we delivered a strong start to 2026, with exceptional top- and bottom-line results that are consistent with our strategic direction

and the scalability of the platforms we’ve built; our belief that our plasma donor compensation business continues to perform exceptionally

well, and the reception to our SaaS solutions from collectors and plasmapheresis manufacturers across the U.S., Europe and Asia reinforces

our conviction that purpose-built technology, backed by deep industry expertise, creates a competitive advantage; our belief that patient

affordability emerged as our largest revenue contributor in the quarter, with 135 active programs and a strong pipeline that reflects

the trust pharmaceutical manufacturers place in us to help patients access and afford the therapies they need; our belief that as this

business grows, we are positioned to deliver long-term value for our shareholders, our customers and the patients we serve; our belief

that our first quarter results exceeded guidance across every line of the income statement; our belief that revenue, operating margin

and net income all finished above the high end of our prior ranges, driven by fixed cost leverage and a continued mix shift toward patient

affordability; our belief that the full-year 2026 ranges, and the momentum from the first quarter supports our continued confidence in

our full-year guidance ranges; our belief that the second quarter reflects the seasonal pattern we have laid out previously: pharma revenue

is highest in the first quarter as patient affordability claims peak, and plasma builds through the balance of the year; our belief that

for the full year, we will continue to expect plasma and pharma to contribute roughly equally to revenue, with margins expanding across

the income statement and net income nearly doubling over 2025 as patient affordability scales; our belief that with a strong unrestricted

cash position, no debt and a growing cash flow profile, we are well positioned to fund our 2026 investment plans and execute against the

financial framework we have communicated; our expectation that we will exit the second quarter of 2026 with 147–150 active patient

affordability programs and 555–560 plasma centers; our belief that non-GAAP measures used by management to gauge the operating performance

of the business help investors better evaluate our past financial performance and potential future results; and our expectations for total

revenues, gross profit margins, operating expenses, depreciation and amortization expenses, stock-based compensation expense, interest

income, tax rate, fully diluted share count, net income, net margin, Adjusted EBITDA and Adjusted EBITDA margin for the second quarter

and full-year 2026. We caution that these statements are qualified by important risks, uncertainties and other factors that could cause

actual results to differ materially from those reflected by such forward-looking statements. Such factors include, among others, the inability

to continue our current growth rate in future periods; the risk that we may not be able to add new patient affordability programs or retain

existing programs at anticipated rates; the risk that plasma center customers may switch to competing providers or close centers, reducing

our revenue; the risk that our outlook and guidance may not be achieved due to factors within or outside our control; that a downturn

in the economy could reduce our customer base and demand for our products and services, which could have an adverse effect on our business,

financial condition, profitability and cash flows; operating in a highly regulated environment; failure by us or business partners to

comply with applicable laws and regulations; changes in the laws, regulations, credit card association rules or other industry standards

affecting our business; changes in the regulatory or legislative environment affecting pharmaceutical patient affordability or copay assistance

programs, including potential restrictions on copay accumulator or maximizer programs; that a data security breach could expose us to

liability and protracted and costly litigation; risks related to the integration of acquisitions, including the Gamma acquisition, and

the realization of anticipated benefits therefrom; and other risk factors set forth in our Annual Report on Form 10-K for the year ended

December 31, 2025. Except to the extent required by federal securities laws, the company undertakes no obligation to publicly update or

revise any statements in this release, whether as a result of new information, future events or otherwise.

About Paysign, Inc.

Paysign, Inc. (NASDAQ: PAYS) operates at the intersection of fintech and

healthcare, integrating advanced payment processing and program management with tailored technologies for the plasma, pharmaceutical and

life sciences industries. Their breakthrough patient affordability solutions ensure patients receive the financial assistance they need

to adhere to prescribed therapies by mitigating the effects of copay accumulators and maximizers. Paysign specializes in blood and plasma

donor compensation programs, as well as comprehensive engagement and management platforms optimized for life sciences. Paysign’s

proprietary processing architecture supports physical, virtual, mobile and bank-based payments with real-time transaction intelligence,

enabling efficient, compliant and scalable program delivery. Through advanced reporting, analytics and in-house 24/7 bilingual customer

support, Paysign delivers measurable value, exceptional service and a superior experience for donors, patients, healthcare providers,

pharmaceutical manufacturers and program sponsors across their growing fintech healthcare ecosystem. The company is committed to improving

efficiencies, reducing costs, streamlining communications, increasing program performance and providing actionable insights to those they

serve.

Contacts:

Investor Relations:

888.522.4810

paysign.com/investors

ir@paysign.com

Media Relations:

Alicia Ches

888.522.4850

pr@paysign.com

Paysign, Inc.

Condensed Consolidated Statements of Operation (Unaudited)

Three Months Ended

March 31,

2026

2025

Revenues

Plasma industry

$ 11,748,611

$ 9,409,880

Pharma industry

15,679,452

8,618,653

Other

610,361

569,616

Total revenues

28,038,424

18,598,149

Cost of revenues

9,819,479

6,907,321

Gross profit

18,218,945

11,690,828

Operating expenses

Selling, general and administrative

8,914,654

7,400,759

Depreciation and amortization

2,636,156

1,801,003

Total operating expenses

11,550,810

9,201,762

Income from operations

6,668,135

2,489,066

Other income

Interest income, net

800,863

762,198

Income before income tax provision

7,468,998

3,251,264

Income tax provision

2,030,080

665,164

Net income

$ 5,438,918

$ 2,586,100

Net income per share

Basic

$ 0.10

$ 0.05

Diluted

$ 0.09

$ 0.05

Weighted average common shares

Basic

55,167,911

53,576,030

Diluted

61,022,060

55,142,511

Paysign, Inc.

Condensed Consolidated Balance Sheets

March 31,

2026

(Unaudited)

December 31,

2025

(Audited)

ASSETS

Current assets

Cash

$ 20,545,119

$ 21,067,651

Restricted cash

158,950,332

143,917,060

Accounts receivable, net

94,248,593

72,191,994

Other receivables

345,228

926,529

Prepaid expenses and other current assets

3,265,549

1,953,717

Total current assets

277,354,821

240,056,951

Fixed assets, net

2,007,393

1,897,892

Intangible assets, net

21,675,898

22,346,213

Goodwill

4,487,637

Operating lease right-of-use asset

5,522,775

5,729,541

Deferred tax asset, net

1,677,104

1,734,969

Total assets

$ 312,725,628

$ 276,253,203

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities

Accounts payable and accrued liabilities

$ 87,539,193

$ 70,542,803

Customer card funding

158,112,295

143,191,068

Operating lease liability, current portion

871,495

751,503

Other liabilities, current portion

1,585,985

1,863,116

Total current liabilities

248,108,968

216,348,490

Operating lease liability, long-term portion

5,048,579

5,273,891

Other liabilities, long-term portion

4,554,666

6,140,651

Total liabilities

257,712,213

227,763,032

Common stock; $0.001 par value; 150,000,000 shares authorized, 56,732,596 and 56,021,596 issued at March 31, 2026 and December 31, 2025, respectively

56,733

56,022

Additional paid-in capital

36,786,545

35,503,253

Treasury stock at cost, 990,955 and 934,708 shares, respectively

(2,348,392 )

(2,148,715 )

Retained earnings

20,518,529

15,079,611

Total stockholders’ equity

55,013,415

48,490,171

Total liabilities and stockholders’ equity

$ 312,725,628

$ 276,253,203

Paysign, Inc. Non-GAAP Measures

To supplement Paysign’s financial results presented on a GAAP basis,

we use non-GAAP measures that exclude from net income the following cash and non-cash items: interest, taxes, depreciation and amortization

and stock-based compensation. We believe these non-GAAP measures used by management to gauge the operating performance of the business

help investors better evaluate our past financial performance and potential future results. Non-GAAP measures should not be considered

in isolation or as a substitute for comparable GAAP accounting, and investors should read them in conjunction with the company’s

financial statements prepared in accordance with GAAP. The non-GAAP measures we use may be different from, and not directly comparable

to, similarly titled measures used by other companies.

“EBITDA” is defined as earnings before interest, taxes, depreciation

and amortization expense. “Adjusted EBITDA” reflects the adjustment to EBITDA to exclude stock-based compensation charges.

EBITDA and Adjusted EBITDA are not intended to represent cash flows from

operations, operating income or net income as defined by U.S. GAAP as indicators of operating performances. Management cautions that amounts

presented in accordance with Paysign’s definition of Adjusted EBITDA may not be comparable to similar measures disclosed by other

companies because not all companies calculate Adjusted EBITDA in the same manner.

Paysign, Inc.

Adjusted EBITDA (Unaudited)

Three Months Ended

March 31,

2026

2025

Reconciliation of EBITDA and Adjusted EBITDA to net income:

Net income

$ 5,438,918

$ 2,586,100

Income tax provision

2,030,080

665,164

Interest income, net

(800,863 )

(762,198 )

Depreciation and amortization

2,636,156

1,801,003

EBITDA

9,304,291

4,290,069

Stock-based compensation

1,284,003

672,318

Adjusted EBITDA

$ 10,588,294

$ 4,962,387

Adjusted EBITDA per share

Basic

$ 0.19

$ 0.09

Diluted

$ 0.17

$ 0.09

Weighted average common shares

Basic

55,167,911

53,576,030

Diluted

61,022,060

55,142,511

“EBITDA margin” is defined as earnings before interest,

income taxes, depreciation and amortization expense as a percentage of the company’s revenue and “Adjusted EBITDA margin”

reflects the adjustment to EBITDA margin to exclude stock-based compensation expense as a percentage of revenue. A reconciliation of net

income margin to Adjusted EBITDA margin is provided in the table below.

Three Months Ended

March 31,

2026

2025

Reconciliation of adjusted EBITDA margin to net income margin:

Net income margin

19.4%

13.9%

Income tax provision

7.2%

3.6%

Interest income, net

(2.9% )

(4.1% )

Depreciation and amortization

9.4%

9.7%

EBITDA margin

33.2%

23.1%

Stock-based compensation

4.6%

3.6%

Adjusted EBITDA margin

37.8%

26.7%

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

May 12, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 12, 2026

Entity File Number

001-38623

Entity Registrant Name

PAYSIGN,

INC.

Entity Central Index Key

0001496443

Entity Tax Identification Number

95-4550154

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2615 St. Rose Parkway

Entity Address, City or Town

Henderson

Entity Address, State or Province

Entity Address, Postal Zip Code

89052

City Area Code

702

Local Phone Number

453-2221

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.001 par value per share

Trading Symbol

PAYS

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration